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Global rate of participation in clinical trials is especially low among African Americans 
in the United States due to social factors identified by research, which adversely impact 
this group’s willingness to participate in clinical trials. The purpose of this cross-sectional 
quantitative study was to evaluate the role of social influence in the decision-making 
patterns of African Americans as it relates to clinical trial participation. The theory of 
planned behavior was used as the theoretical framework to understand an individual’s 
interaction with social factors and how it affects their willingness to participate in clinical 
trials. The participants in the study were 115 African Americans residing in a greater 
metropolitan area of Ohio. Data were collected using 1-time questionnaire administered 
by paper instrument. Regression and correlation analyses were conducted for all 115 
collected survey responses. Results of the analyses were statistically significant in 
proving that social influence is a good predictor of willingness to participate in clinical 
trials where the research involves minimal risk to the participants (p = 0.047). The results 
also showed that attitudes and beliefs about clinical trials are good predictors of 
willingness to participate in clinical trials among African Americans (p = 0.000). The 
results of this study offer new insight for the development of patient recruitment 
initiatives within the African American community in the United States and create a path 
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Chapter 1: Introduction to the Study 
Introduction 
Clinical trials explore the safety and efficacy of novel drugs or devices used in the 
treatment of new or existing diseases in humans and highlights the best medical treatment 
that best serves a certain group of people (National Institutes of Health [NIH], 2017). 
There is a general acceptance by the medical community as well as the public of the 
importance of advancing medical knowledge (Center for Information & Study on Clinical 
Research Participation, 2012; Steinke, 2004). Notwithstanding these facts, together with 
the overall acceptance of the benefits of clinical trials, global rates of clinical trials 
participation is low in the United States (Lee, Ow, Lie, & Dent, 2016). This issue is of 
great concern, particularly among African Americans and other ethnic minorities, and 
little or no improvement has been recorded over the years (Hughes, Varma, Pettigrew, & 
Albert, 2017; Lang et al., 2013). Clinical trial participation numbers have seen a decrease 
in the past 30 years, a decline which is expected to continue in the coming years (Galea & 
Tracy, 2007; Rogers, Murtaugh, Edwards & Slattery, 2004).  
The burden of disease data in the United States confirms that African Americans 
stand a higher risk of morbidity and early mortality than other races (Noonan, Velasco-
Mondragon, & Wagner, 2016). Research has shown that race and ethnicity are correlated 
with the growing health disparities in the United States (Noonan, Velasco-Mondragon, & 
Wagner, 2016). Nonetheless, there is an increase in the lack of willingness to participate 
in clinical trials and recruitment of African Americans for participation in these trials 
continues to be a discouraging task (Anwuri et al., 2013). There is a need for more 
2 
 
research into the factors that are specific to the African American population, including 
the behaviors that promote the lack of willingness to participate in clinical trials in the 
United States. The inability to develop a viable strategy to overcome this issue raises a 
concern regarding the future of clinical trials that are generalizable to all races and 
ethnicities in the United States (Hughes et al., 2017).  
The problem of low ethnic minority participation in clinical trials is significant to 
public health because adequate therapies to cure illnesses result from extensive research 
in the targeted population. African American representation in clinical trials is needed 
because they have a greater risk of morbidity and early mortality compared to other races 
in the United States (Noonan et al., 2016), and race and ethnicity correlates with the 
rising health inequalities in the United States (Fisher & Kalbaugh, 2011). Research that is 
considered ethical and scientifically sound must include a sample population that is 
representative of the population (George, Duran, & Norris, 2014; Hughes et al., 2017).  
Willingness represents an individual’s inclination or favorable mental disposition 
towards an action (“Willingness,” 2017). African Americans differ from European 
Americans and other ethnic groups in their willingness to participate in clinical trials, and 
this issue has been attributed to a host of factors including a low level of trust of medical 
research (Bruce et al., 2014; Tanner, Kim, Friedman, Foster, & Bergeron, 2015). 
Previous research studies have provided conclusions that suggest a link between social 
factors operating within a group and their willingness to participate in clinical trials 
(Bruce et al., 2014; Tanner et al., 2015). In a literature review conducted by Luebbert and 
Perez (2016), the authors reported that the barriers to willingness to participate in clinical 
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trials among African Americans included issues related to trust, experimentation, 
communication, and logistics. Hughes et al. (2015) concluded that fear and lack of trust 
for research were the most common barriers to participation in clinical trials among 
African Americans. These barriers were attributed to factors like lack of information 
related to the research and prevailing knowledge of historical instances of unethical 
research practices (Hughes et al., 2015). Other social factors like racism (Sherman, 
Hawkins, & Bonner, 2017; Speights et al., 2017), attitudes towards research (Bruce et al., 
2014), fear of being used as guinea pigs (Hughes et al., 2015; Tanner et al., 2015), and 
socioeconomic status (Chen, Lara, Dang, Paterniti, & Kelly, 2014; Unger et al., 2013) 
have also been identified.  
The younger generation of African Americans who have not directly experienced 
or have direct evidence of unethical practices against ethnic minorities may rely on 
inaccurate information as it relates to clinical trials, passed on from parents or older, 
earlier generations through storytelling (Lee, Fawcett, & DeMarco, 2016; Palacios et al., 
2015). The authority influence hypothesis proposed by Schöbel, Rieskamp, and Huber 
(2016) predicts that  
people’s behavior will also be influenced by the hierarchical status of other 
decision makers and will make decisions that conform to higher ranked others’ 
decisions more often, even if other available public information and their own 
private information suggest doing otherwise (p. 5).  
According to Hughes et al. (2015), one of the most commonly identified barriers to 
participation is the historical occurrences of past unethical research practices. Through an 
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individual’s interaction with these sociocultural factors, these valid historical occurrences 
could easily be mixed up with urban legends and then passed down through generations 
in the African American community (Hughes et al., 2015).  
Social influence represents the changes in behavior, opinion, or beliefs that 
individuals initiate, based on interactions with the prevailing social factors (Moussaïd, 
Kämmer, Analytis, & Neth, 2013). It represents the process through which an individual 
can adapt their opinions, revise their beliefs, or adjust their behavior, resulting from 
social interactions with others (Moussaïd, Kämmer, Analytis, & Neth, 2013). The role of 
social influence in potentially diminishing the willingness of African Americans to 
participate in clinical trials is not well established. Due to unfavorable health outcomes in 
the African American community, it is important to identify the process by which the 
history of unethical practices against this population continues to be at the forefront of all 
identifiable barriers to research, despite great advances in research participant protections 
and research ethics in the United States. The answer to this could lie in an African 
American’s recognition of the activities that apply to them based on their desire to 
conform to a behavior or norm developed through sociocultural values (Moussaïd et al., 
2013).  
The barriers to African American participation in clinical trials have been 
examined by different researchers (e.g., Anwuri et al., 2013; George et al., 2014; Lee et 
al., 2016). However, these barriers have not been effectively linked to the ever-present 
impact of social influence. More research is needed to evaluate trends that support the 
role played by social influence in either encouraging or discouraging the willingness of 
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African Americans to participate in clinical trials because an individual’s social 
conditions, environmental exposures, and past experiences work together to produce 
behavior and motivation (see Garza et al., 2017; Moussaïd et al., 2013). Common 
opinions are created by common cultural beliefs, and according to Moussaïd et al. (2013), 
opinions are more likely to be reinforced by group discussions conducted by individuals 
with similar judgement. The results of this study provide much needed insight into this 
issue that impacts health promotion because failure to increase the participation rates of 
African Americans in clinical trials will inhibit the progress of clinical trial research into 
novel and effective methods in drug development (see Frew, Schamel, O’Connell, 
Randall, & Boggavarapu, 2015). 
Background of the Problem 
African Americans represent approximately 13.3% of the U.S. population (U.S. 
Census Bureau, 2016) and continue to experience an unequal burden of disease, limited 
access to health and health care services, and lower life expectancy when compared to 
other races (Correa-de-Araujo, 2017; Frist, 2005). When compared to other races, 
African Americans differ unfavorably in their willingness to participate in clinical trials 
(Kurt et al., 2016; Shavers, Lynch, & Burmeister, 2002), representing only 5% of all 
clinical trials participants in the United States (Hughes et al., 2015). This issue has been 
attributed to a host of factors, including distrust for medical research (Kurt et al., 2016; 
Shavers et al., 2002; Stuchlik et al., 2015), resulting from a history of unethical practices 
and harsh treatments that were meted out to the African Americans (e.g., the Tuskegee 
Study; Durant, Legedza, Marcantonio, Freeman, & Landon, 2011). Several researchers 
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have proposed that the distrust resulting from the Tuskegee Study is the major 
impediment for the willingness of African Americans to participate in clinical trials 
(Sacks, 2015). Shavers, Lynch and Burmeister (2000) reported that 81% of the 179 
African American adult participants in their study had knowledge of the Tuskegee Study. 
The researchers also found that this knowledge directly influences their level of trust for 
medical research (Shavers et al., 2000). Knowledge of historical instances of unethical 
practices is further compounded by present feelings of comparable mistreatment  
Although there is a mandate by federally funded agencies to include racially 
diverse populations in clinical trials, the enrollment of African Americans in clinical 
trials remains a discouraging task (Hughes et al., 2015). Data shows that although African 
Americans make up 12.4% of the entire U.S. population, only 5% of clinical trials 
participants in the United States are African Americans (Fisher & Kalbaugh, 2011; 
Hughes et al., 2015). The current gap in research needed to understand this issue and the 
inadequacy in the development of a practical approach to overcome the issue raises a 
concern regarding the future of research into treatments for race-specific diseases like 
sickle cell disease, as well as concern for the ability of researchers to generalize clinical 
trials results to the entire population (Hughes et al., 2015).  
It is important to understand the impact of social influence, an intricate inherent 
human factor that holds the potential to impact attitudes and behaviors, on the decision-
making patterns and the willingness to participate in clinical trials among African 
Americans. An individual’s partner or family members can influence their willingness to 
participate in clinical trials, and this was concluded to be greater in clinical trials 
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conducted in developing countries than in developed countries (Lobato et al., 2014). This 
finding was attributed to the influence of culture identification, which promotes 
interdependence (Lobato et al., 2014). In a multicenter study of hypertension and genetics 
by Marshall et al. (2006), 47% of female participants enrolled in Nigeria solicited the 
guidance of their partners prior to participating in the research compared to the U.S.-
enrolled female participants of which none solicited the advice of a partner before 
participation. Banks-Wallace (2002) reported that storytelling, which is a part of the core 
of the African American culture, can also affect behavior. When life events or 
experiences are considered, this process of storytelling could create a communal 
experience that links the teller to the listener, thereby promoting similar behavior and 
attitudes (Banks-Wallace, 2002). The mistrust exhibited by African Americans for 
healthcare services and healthcare providers as well as other institutions has survived 
many generations.  
With this study, I shed light on the existence of the concept that social influence, 
as an intricate inherent human factor, holds the potential to impact attitudes and behaviors 
related to willingness to participate in clinical trials. The results of this study provide a 
better understanding of the positive and/or negative impact of social influence factors 
(i.e., culture, beliefs, values, attitudes, and learned individual preferences) on clinical 
trials and contribute to ongoing research into developing methods to maximize ethnic 
minority participation in clinical trials in the United States (see Branson, Davis, & Butler, 
2007). Some research studies aimed at identifying barriers to participation in clinical 
trials among African Americans have been replicated without specifically capturing and 
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assessing the role played by social influence, a core factor when evaluating behaviors 
within a culturally unique population, thus making my research the logical next step to 
assess how social factors may influence willingness. (see Marshall et al., 2006). In this 
study, I looked at the impact of social influence on an African American’s willingness to 
participate in clinical trials. The findings of the study shed light on how information 
passed from generation to generation through storytelling affects current behaviors 
related to research participation decisions and lends significance to a common goal of 
equity and equality in health care services and delivery.  
Problem Statement 
There is an unequal burden of disease, limited access to health and health care 
services, and lower life expectancy among African Americans when compared to other 
races (Frist, 2005). This issue is worsened by a systemic underrepresentation of African 
Americans in clinical trials, including clinical trials which target race-specific diseases 
(e.g., sickle cell disease), culminating in shortfalls in data generated from clinical trials 
and limiting the ability of researchers to generalize the results to the entire U.S. 
population (Frist, 2005). Information regarding the impact of newly developed therapies 
used in the treatment of diseases that affect the African American population is limited, 
and although there are government regulations aimed at enforcing ethnic minority 
participation in government-funded research, African Americans as well as other 
minorities remain underrepresented in important clinical trials (Sanders, 2011). 
Therefore, the problem I addressed in this study was the inability of researchers to 
generalize clinical trial results and to develop new therapies targeting diseases that are 
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prevalent in the African American population. I addressed this issue by identifying the 
role played by social influence and its effectiveness and potential use in the development 
of viable interventions. 
Purpose of the Study 
I designed this study to identify how social influence affects the willingness of 
African Americans to participate in clinical trials as a platform for the development and 
implementation of interventions to improve clinical trial participation among this 
population. In this study, I methodically examined and elucidated the potential 
association between the willingness of African Americans to participate in clinical trials 
and predisposing variables that included social influence and other demographics (i.e., 
gender, age, employment status, and family history of research participation; Chen et al., 
2014). The theory of planned behavior was used as the framework to guide the research 
questions. 
Study Population 
The population for this study included African Americans, aged 18 years and 
older, who resided in a greater metropolitan area of Ohio. In this study, I defined African 
Americans as individuals who are Black and are of African descent and who identify as 
Black, African, or African American. This definition ensured the inclusion of a broader 
range of individuals for the study. 
The racial make-up of the city is 49.3% White, 44.8% Black or African 
American, 1.8% Asian, 2.8% Hispanic or Latino, and 0.3% American Indian or Native 
Americans (U.S. Census Bureau, 2017). The population of people 18 years or older in the 
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city is 232,150, of which African Americans make up 41% (U.S. Census Bureau, 2017). 
 
Figure 1. Racial demographics (U.S. Census Bureau, 2017) 
 Of the 30.5% of the city’s population who live below the poverty line, 42.3% are 
African Americans (U.S. Census Bureau, 2017). There are mixed reports regarding the 
impact of socioeconomic status on health care trust among African Americans 
(Hammond, 2010; Rajakumar, Thomas, Musa, Almario, & Garza, 2009; Watkins et al., 
2012). However, Guerrero, Mendes de Leon, Evans, and Jacobs (2015), in a study 
exploring the differences in socio-demographic and psychological correlates of 
institutional trust in health care among older African Americans and other minorities, 
concluded that psychological factors played a more prominent role in health disparities 
among older African Americans. Social interactions and the impact of the environment 











Research Questions and Hypotheses 
The research questions I developed for this study were primarily focused on the 
socio-cultural factors that influence the willingness to participate in clinical trials among 
African Americans aged 18 years and older. The following research questions and 
corresponding hypotheses guided this dissertation: 
Research Question 1: What is the relationship between knowledge of clinical 
trials and willingness to participate in clinical trials among African Americans? 
H01: There is no statistically significant relationship between knowledge 
of clinical trials and willingness to participate in clinical trials among 
African Americans. 
HA1: There is a statistically significant relationship between knowledge of 
clinical trials and willingness to participate in clinical trials among African 
Americans. 
Research Question 2: What is the relationship between attitude and beliefs and 
willingness to participate in clinical trials among African Americans? 
H02: There is no statistically significant relationship between attitude and 
beliefs and willingness to participate in clinical trials among African 
Americans. 
HA2: There is a statistically significant relationship between attitude and 




Research Question 3: Does social influence within the African American 
community affect the willingness of an African American to participate in clinical 
trials? 
H03: There is no statistically significant relationship between social 
influence within the African American community and the willingness of 
an African American to participate in clinical trials. 
HA3: There is a statistically significant relationship between social 
influence within the African American community and willingness of an 
African American to participate in clinical trials. 
Assumptions 
My first assumption for this study was that the validated survey instrument would 
be fully completed by all research participants once administered. I also assumed that 
research participants would have the necessary educational level to read and understand 
the content of the survey with no difficulty and that they would truthfully answer the 
questions. Another assumption was that the lack of willingness to participate in clinical 
trials is a known phenomenon within the African American community and may have 
limited the participation rates in this study. Finally, I assumed that the results of this 
research could provide guidance for the development of interventions aimed at improving 
African Americans participation in clinical trials. 
Limitations 
I identified some factors that could have limited the findings of this study. These 
include the potential for incomplete surveys being submitted by participants as well as a 
13 
 
possible low level of honesty in the responses. The responses from the participants may 
have been influenced by my presence, skewing the results. Another limitation laid in the 
fact that the quality of a quantitative research depends profoundly on the researcher’s 
efficiencies and is influenced by individual predispositions of the researcher (see 
Anderson, 2010). Furthermore, due to the planned data collection method, in which only 
church attendees who agreed to participate in the research were included, the results may 
not be generalizable to all church attendees in a greater metropolitan area of Ohio. 
Although a previous study reported that religiously based differences on social issues are 
less evident among African Americans compared to the overall population, with 53% of 
African Americans polled reporting attending religious services at least once a week 
(Sahgal & Smith, 2016), the results of this study may not be generalizable to the entire 
African American population because of differences in opinions that may exist among 
church goers vs. non-church goers. 
Delimitations 
This study included only African Americans residing in a greater metropolitan 
area of Ohio. Recruitment of other ethnic groups did not fit in the boundaries of the 
study. The choice of the geographic location for this study was based on ease of conduct 
and the availability of a higher population of African Americans in the selected area in, 
Ohio. 
Definition of Terms 




Clinical trial: A process used to evaluate the safety and efficacy of medical 
strategy, treatment, or device in humans and that highlights the best medical treatment 
that best serves a certain group of people (NIH, 2017). 
Social influence: Changes in behavior, opinion, or beliefs that individuals initiate 
based on interactions with the prevailing social factors. It represents the process through 
which an individual can adapt their opinions, revise their beliefs, or adjust their behavior, 
resulting from social interactions with others (Moussaïd, Kämmer, Analytis, & Neth, 
2013). 
Willingness: An individual’s inclination or favorable mental disposition towards 
an action (“Willingness,” 2017). 
Implications for Social Change 
Failure to increase the participation rates of African Americans in clinical trials 
will inhibit the progress of clinical trial research into novel and effective methods in drug 
development (Frew et al., 2015). I designed this study to identify how social influence 
affects the willingness of African Americans to participate in clinical trials as a platform 
for the development and implementation of interventions to improve clinical trial 
participation among this population. This study will serve as a starting point for further 
research into the interactions stated in the focus of this study. 
Summary 
Clinical trial participation is an intricate part of advancing medical science and 
drug development. Notwithstanding the acceptance by most Americans, the overall 
participation numbers continue to see an uncontrolled decline (Anwuri et al., 2013). Low 
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rates of participation in clinical trials ultimately impact advancements in medical science, 
the health of the nation, and eventually the economy of our nation. In this chapter, I 
examined the potential link between the low participation rates among African 
Americans and social influence, which represents the process through which an 
individual can adapt their opinions, revise their beliefs, or adjust their behavior, resulting 
from social interactions with others. An understanding of this interaction will be of 
benefit to clinical researchers by enabling the identification and elimination of barriers to 
participation among African Americans. In the next chapter I reviewed some existing 
literature which highlight results that support the existence of a relationship between 
social factors and willingness to participate in clinical trials. 
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Chapter 2: Literature Review 
Introduction 
In this chapter, I will provide a review of relevant literature related to people’s 
willingness to participate in clinical trials and African Americans’ willingness 
specifically, focusing on the roles of distrust and other barriers created by the historical 
knowledge of unethical practices against African Americans and other ethnic minorities 
in the United States. I will also review literature related to the potential effects of 
normative social influence and sociocultural norms like generational information sharing 
on knowledge, attitude, and beliefs (KAB) towards participation in clinical trials. 
Literature related to social norms that impact health behavior will also be reviewed. 
The NIH (2017) defined a clinical trial as “A research study in which one or more 
human subjects are prospectively assigned to one or more interventions” (p. 4). Clinical 
trials (also known as clinical treatment research) is medical research through which 
researchers witness the progression of a disease or condition in human beings to assess 
the effectiveness of a drug or therapy (Brown & Topcu, 2003). Clinical trials serve to 
explore the efficacy and safety of various medicinal treatment strategies in humans (NIH, 
2014). The problem of low ethnic minority participation in clinical trials is significant to 
public health because there is a greater risk of morbidity and early mortality among 
African Americans compared to other races in the United States and race correlates with 
the rising health inequalities in the United States (Fisher & Kalbaugh, 2011). I aimed this 
systematic literature review at elucidating the interactions between social influence and 
willingness to participate in clinical trials. Several factors have been identified by 
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researchers that affect willingness to participate in clinical trials including age, 
race/ethnicity, gender, socioeconomic status, education, health status, knowledge about 
clinical trials, perceived risk or benefit, compensation, altruism, and trust.  
Search Strategy 
I located the information presented in this literature review using peer-reviewed 
journal articles and books found through the EBSCO Research Database, PubMed, and 
Google Scholar. I focused on literature published within the past 5 years. My search 
strategy for identifying relevant literature consisted of Boolean combinations of the 
following terms: social influence, normative social influence, willingness, African 
Americans AND clinical trials, African Americans AND clinical research, African 
Americans AND clinical trials, barriers to research participation, Tuskegee Study and 
distrust, African American AND research willingness, distrust AND research, cultural 
distrust, storytelling, historical trauma, social influence, Tuskegee experiment, unethical 
experiments AND African-Americans, social distrust, fear of research, and African 
American knowledge of research.  
Developing Social Influence Concept 
Individuals within a community regularly make decisions in a social environment; 
they are more likely to adopt the opinion of others while ignoring their own, with little or 
no regard to the accuracy of the information (Schöbel et al., 2016). Most human decisions 
are made in a framework of highly multifaceted social interactions, and many of an 
individual’s decisions are influenced by the behavior of others (Hertz, Romand-Monnier, 
Kyriakopoulou, & Bahrami, 2016). Social influence represents the changes in behavior, 
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opinion, or beliefs that an individual may initiate based on interactions with the 
prevailing social factors and the process through which an individual can adapt their 
opinions, revise their beliefs, or adjust their behavior, resulting from social interactions 
with others (Moussaïd et al., 2013). There are two types of social influence that are 
helpful in explaining human conformity: normative social influence and informational 
social influence (Schöbel et al., 2016). The former, which was the focus of this study, 
defines behavior motivated by an individual’s desire to achieve an appreciated, clear self-
identity, followed by an expression of a defined impression to others (Schöbel et al., 
2016). The latter defines behavior that is developed from valuable information provided 
by another individual’s opinion and used to improve judgement or a decision (Schöbel et 
al., 2016). 
Although the impact of social influence on the willingness of African Americans 
to participate in clinical trials could be positive or negative, my focus in this study was to 
understand how social influence serves to deter most African Americans from 
participating in clinical trials. Research has documented associations between 
sociocultural factors and health; however, the role of social influence in potentially 
diminishing the willingness of African Americans to participate in clinical trials is not 
well established (Berkman & Kawachi, 2000; Marmot & Wilkinson, 2006).  
Since common opinions are created by common cultural beliefs, and per 
Moussaïd et al. (2013), opinions are more likely to be reinforced by group discussions 
conducted by individuals with similar judgement, it is important to identify the process 
by which the history of unethical practices against this population continues to be at the 
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forefront of all identifiable barriers to their participation in research, despite great 
advances in research participant protections and research ethics in the United States. The 
answer to this could be present in African Americans’ recognition of the activities that 
apply to them based on their desire to conform to a behavior or norm developed through 
sociocultural values (Palacios et al., 2015). There are social factors beyond the memories 
of the Tuskegee Study that play a role in negatively influencing African Americans’ 
willingness to participate in clinical trials (Saleem et al., 2016).  
Some researchers have argued that the history of abuse and unethical practices 
may not be the direct driver of societal distrust in clinical trials (Durant et al., 2011; 
Saleem et al., 2016), making it plausible that social factors (i.e., opportunity, income, 
ethnic minority status, and health conditions), which are antecedents of inequity in the 
U.S. society, could contribute to African Americans’ lack of willingness to participate in 
clinical trials (Lang et al., 2013). An individual’s social conditions, environmental 
exposures, and past experiences work together to produce behavior and motivation 
(Boulware et al., 2016). Individuals also apply differential weighting to social 
information based on the authority of other individuals who are decision makers, and this 
influence of authority is at its highest strength when the decision of an individual with 
authority contrasts with private information (Schöbel et al., 2016). 
 Conformity behavior has been shown to be motivated by developing and 
maintaining acceptance (Schöbel et al, 2016). The results of this study provide insights 
into the effects of the relationship between social influence and the willingness of African 
Americans to participate in clinical trials as a benefit to health promotion.  
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The Concept of Storytelling 
Storytelling is an age-old institution that exists among different communities and 
cultures around the world. Information sharing preserves cultural beliefs and practices 
from generation to generation, and most people will remember most negative actions 
towards them to avoid similar actions in the future (Barton & Barton, 2017). Stories have 
been found to play a vital role in the lives of individuals across various age groups and 
diverse backgrounds (Barton & Barton, 2017). The impact of storytelling in native 
communities is well documented for cultural and historical legacy and communication 
(Barton & Barton, 2017). The younger generation can form and build a strong identity 
that could potentially affect their ability to develop immediate opinions about well-
established issues like racism and distrust for the healthcare community (Barton & 
Barton, 2017). According to Eder (2010), through storytelling, children are empowered 
to frame their understanding of multifaceted moral issues within a society. 
Nolan et al. (2008) suggested that normative information could be an 
underdetected source of influence on behavior. The behavior of younger African 
Americans who are apparent descendants towards clinical trials continues to be affected 
by the narratives that originated from the Tuskegee Study (Sacks, 2015). Storytelling can 
affect behavior and when life events or experiences are considered, this process of 
storytelling could create a communal experience that links the teller to listener, thereby 
promoting similar behavior and attitudes (Banks-Wallace, 1998; 2002; Larkey et al., 
2015; Palacios et al., 2015). The mistrust exhibited by African Americans for healthcare 
services and healthcare providers as well as other institutions has survived many 
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generations. Evidence of this assumption may be found in the fact that younger African 
Americans with little or no negative experience exhibit similar levels of mistrust for 
clinical trials (Sacks, 2015). 
An Examination of Willingness Among African Americans 
African Americans differ from European Americans and other ethnic groups in 
their willingness to participate in clinical trials, and this issue has been attributed to a host 
of factors including a low level of trust of medical research (Meng, McLaughlin, Pariera, 
& Murphy, 2016; Shavers et al., 2002). Trust has been suggested as an antecedent to 
willingness (Chu, Kim, Jeong, & Park, 2015), and there is a clear distinction in the level 
of trust between African Americans and other races in the United States (Meng et al., 
2016). African Americans may not be willing to participate in clinical trials due to the 
influence of family members as well as fears inculcated through cultural beliefs and 
folklore (Hammond, 2010; Meng et al., 2016). This idea is supported by research, which 
suggested that a link exists between social factors operating within a group and their 
willingness to participate in clinical trials (Meng et al., 2016). 
Willingness to participate in clinical trials among African Americans includes 
barrier issues related to trust, experimentation, communication, and logistics (Luebbert 
and Perez, 2016).  Fear and lack of trust for research were the most common barriers to 
participation in clinical trials among African Americans (Hughes et al. 2015). These 
barriers have been attributed to factors like lack of information related to the research and 
prevailing knowledge of historical instances of unethical research practices (Hughes et 
al., 2015). Other social factors like racism, attitudes towards research, fear of being used 
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as guinea pigs, psychological barriers to recruitment, and socioeconomic status have also 
been identified (Boulware et al., 2016; George et al., 2014; Tanner et al., 2015). Most 
African Americans do not have a positive perception of safety and favorable feeling 
towards clinical trials (Hughes et al., 2015). Research has shown that there is an increase 
in the likelihood that a person would participate in clinical trials based on their perception 
of safety, and there is a strong association between perceived wellbeing, advantageous 
feeling, and willingness to participate in clinical trials (Chu et al., 2015).  
Health Disparities Experienced by Black or African Americans 
The Centers for Disease Control and Prevention (2017) defined disparities as the 
existence of differences in the incidence, prevalence, and mortality of a disease, together 
with its related adverse health outcomes, among specified populations. African 
Americans represent approximately 13.3% of the U.S. population (U.S. Census Bureau, 
2016) and continue to experience an unequal burden of disease, limited access to health 
and health care services, and lower life expectancy when compared to other races 
(Correa-de-Araujo, 2017; Frist, 2005). It is not coincidental that the African American 
population is the least healthy group in the United States. Dublin (1928) stated that 
“improving the health of African Americans to a state where it compares favorably with 
that of Caucasians, would easily eliminate the many disabilities which plague the African 
American population and improve its economic status” (p. 80). There are social factors at 
work, deeply rooted in the history of African Americans in the United States, which 
continue to impact the overall health of this population (Noonan et al., 2016). Social 
determinants of health disparities (i.e., poverty, housing, education, access to healthcare, 
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environmental exposures, and racism) continue to play a vital role in the health and 
wellbeing of African Americans (Noonan et al., 2016). Racism, which is correlated with 
deficiencies in education, housing, income, and access to health services, continues to 
affect the overall health of this population (Noonan et al., 2016). There is evidence that 
race, as a factor in health disparities, is not moderated by other factors like age, sex, and 
educational level (Paradies et al., 2015). There is also documented evidence of a 
relationship between perceptions of racism and mistrust for healthcare providers; the 
perception of racism has been shown to have a significant negative effect on the trust and 
satisfaction with care (Bankert, Peters, Clark, & Keeves-Foster, 2006).  
African Americans and Participation in Clinical Trials 
Although the burden of disease is higher among African Americans when 
compared to other ethnic minorities, and African Americans are at a greater risk of 
morbidity and early mortality (Fisher & Kalbaugh, 2011), participation of African 
Americans in current clinical trials continues to be a difficult task for the drug 
development industry (Fisher & Kalbaugh, 2011). There is evidence of low participation 
in clinical trials among all minorities in the United States (Chen et al., 2014; Shavers et 
al., 2002) with most research identifying distrust for medical research as the main cause 
of the issue (Hughes et al., 2015; Luebbert & Perez, 2016; Shavers et al., 2002). The 
global rates of participation in clinical trials is low, particularly among ethnic minorities 
in the United States, and this issue has not seen an improvement over the years (Hughes, 
et al., 2017; Lang et al., 2013). African Americans are particularly at a disadvantage from 
the unintended consequence of this issue (Hughes et al., 2017). 
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Quantitative and qualitative research examining the barriers and facilitators to 
clinical trials participation among African Americans has revealed numerous notable 
barriers. The barriers include lack of awareness regarding clinical trials, mistrust, fear of 
research, and fear of adverse consequences (Corbie-Smith, Thomas, & George, 2002; 
George et al., 2014; Owens, Jackson, Thomas, Friedman, & Hébert, 2013). Altruism, the 
desire to help others or their community, has been identified as a one of the main 
facilitators for clinical trial participation by African Americans (Shavers, 2001). Others 
include access to healthcare and healthcare services, perceived risk, and compensation 
(Brown & Topcu, 2003; Byrne, Tannenbaum, Glück, Hurley, & Antoni, 2014).  
In a study conducted by Lang et al. (2013), they aimed at clarifying the factors 
which impact African American willingness to participate in health-related research, the 
researchers concluded that the willingness to participate in clinical trials exists among 
this population. Their results showed that over 70% of the clinical trials naïve participants 
in the study expressed willingness to participate in clinical trials (Lang et al., 2013). This 
group consisted mostly of younger adults (<40 years old) who also attained a higher level 
of education that the other participants. The researchers also pointed out that trust was an 
impediment to participation and that participants with knowledge of the Tuskegee 
Syphilis Study were 50% less likely to show willingness to participate in clinical trials 
(Lang et al., 2013). Although this willingness exists, consideration must be given to the 
unique sociocultural factors which exist within the African American community through 
which behaviors are formed and decisions are made based on local and community 
beliefs (Lee et al., 2016). 
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African Americans and Distrust of the Medical Community 
The various past and present medical atrocities which African Americans have 
been victims of have led to a lack of trust for the medical community in the United States. 
Research has shown that African Americans are less likely to participate in research and 
exhibit more distrust of the medical community than any other ethnic group in the United 
States (Boulware et al., 2016; Mokwunye & Nneka, 2006). There is also documented 
evidence that African Americans continue to believe that the medical community, 
possibly due to poor communication, do not acknowledge their perspective during their 
interactions (Cuevas, O’Brien, & Saha, 2016). A combination of personal and passed-on 
experiences and ongoing reiteration of doubts has led to a strong assertion of distrust over 
the years in African American communities (Cuevas et al., 2016). The legacy of racism 
and racial discrimination in healthcare is linked to the issue of lack of trust in medical 
research among African Americans and its perception has become imbedded in the 
sociocultural behavior of this population towards participation in all things related to 
health and clinical trials (Boulware et al., 2016). 
There are differences in the level of distrust for clinical trials among African 
Americans based on age (Boulware et al., 2016); thus making it logical to assume that the 
issue of distrust in medical research should reside mostly among the elderly African 
Americans, who may have been directly impacted by landmark episodes of unethical 
research practices, and less with the younger generation, raised in an era where stringent 
regulations prevent such brash occurrences. This idea is supported by research, which 
concluded that convincing older African Americans to participate in clinical trials has 
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been and continues to be a difficult task, despite unfavorable health disparities that they 
experience in the United States (Sabir & Pillemer, 2014). The term distrust, as used in 
this research encompasses the both cultural mistrust and medical mistrust. Cultural 
mistrust is defined as an inclination among African Americans to distrust European 
Americans (Terrell & Terrell, 1981). Research has shown that distrust of the health care 
system could be an important barrier to individuals’ willingness to seek healthcare 
services, adhere to preventive health care and treatment regimens, as well as participate 
in clinical trials (Rose, Peters, Shea, & Armstrong, 2004).  
Patients who exhibit greater trust in their healthcare providers are more likely to 
consent to participation in clinical trials (Westergaard, Beach, Saha, & Jacobs, 2014). A 
widely-accepted assumption is that under-representation of African Americans in clinical 
trials is a result of less willingness to participate due to mistrust and fear created by a 
history of unethical practices (Stuchlik et al., 2015). There is a greater distrust for clinical 
trials within the African American community when compared to the Caucasian 
community (Durant et al., 2011; Fisher & Kalbaugh, 2011). This distrust among African 
Americans has been attributed to the history of unethical practices and harsh treatments 
that were meted out to the African Americans in the past e.g. Tuskegee Airmen Study 
(Durant et al., 2011). There are many in the African American community for whom the 
memories of the Tuskegee Study preserved in their thoughts and decisions related to 
health care services are informed by these memories both on an individual as well as on a 
group level (Doucet-Battle, 2016).  
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Although distrust and socio-cultural factors have been identified as the leading 
cause of the lack of or reduced willingness of African Americans to participate in clinical 
trials, Anwuri et al. (2013) provided background for other potential factors, which may 
play a role in the process, which leads to the decision not to participate in clinical trials. 
These factors include individual-level factors like fear, faith, culture; interpersonal-level 
factors like healthcare provide-patient relationship and information sharing about 
research within family boundaries; institutional-level factors like physician training, 
regulations, and limited minority patient pools; and public policy-level factors like 
federal mandates (Anwuri et al., 2013).  
The impact of knowledge regarding research cannot be diminished. Research 
conducted using a hypothetical setting showed that an informed consent process which 
encompasses teaching regarding the clinical trials processes and safeties currently in 
place to protect subjects, increases the number of patients who are willing to 
participate in clinical trials. The researchers concluded that there was a significantly 
lower likelihood of patients receiving pre consent education to refer to factors like 
mistrust, fear of adverse effects, absence of perceived benefits, and patient privacy as 
reasons for lack of willingness to participate (Dunlop et al., 2011). Though well 
recognized and widely researched with over 20 years of a statutory directive to promote 
actions that increase inclusion of minorities in government-funded clinical trials, low 
rates of participation of African Americans in clinical trials continues to be an issue 
(Chen et al., 2014; Chu et al., 2015). This supports the conclusion by researchers of the 
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existence of inherent social factors within this populations that drive low participation in 
clinical trials (Chen et al., 2014). 
Other Barriers to Clinical Trials Participation Among African Americans 
There are various barriers that have been identified in research as the leading 
factors that limit the willingness of African Americans to participate in clinical trials. 
Various studies have identified the following factors as important barriers to willingness 
to participate in clinical trials. These include: age, race/ethnicity, gender, socioeconomic 
status, education, health status, perceived risk or benefit, altruism, distrust, and 
knowledge of clinical trials (Advani et al., 2003; Boulware et al., 2016; DeFreitas, 2010; 
Ding, et al., 2007; Dunlop et al., 2011; Dunn et al., 2009; Durant et al., 2011; Holman et 
al., 2010; Israni et al., 2004; Lee et al., 2005; Mathews et al., 2009; Sabir & Pillemer, 
2014; Shavers et al., 2002; Volkmann et al., 2009; White & Hardy, 2010). This study 
focused on the barriers that are moderated or amplified by the unique sociocultural 
factors which exist within the African American community. It is important to understand 
the point at which altruism is overcome by fear, and how social influence lends weight to 
distrust in the African American community.  
Theoretical Foundation 
Fishbein and Ajzen’s theory of planned behavior (TPB) served as a conceptual 
framework for this study. As a well-established and recognized social cognitive theory, 
the TPB has been broadly used to effectively predict and elucidate different health 
behaviors and intentions to include health service utilization (Sicilia, Sáenz-Alvarez, 
González-Cutre, & Ferriz, 2015). The TPB model is based on a belief that assumes that 
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the intention of an individual to exhibit a behavior is an important determinant for 
exhibiting that behavior (Ajzen & Madden, 1986). The extent to which an individual will 
plan and develop their efforts leading to the expression of a behavior defines intention 
(Ajzen & Fishbein, 1980). Intention is a motivational construct which is determined by 
attitudes towards the behavior, subjective norms, and perceived behavioral control 
(Ajzen, 1991); and defined as the probability that an individual will exhibit a specific 
behavior in specific conditions, regardless of the outcome. The development of this 
model was preceded by works of social psychologists who suggested “attitudes could 
explain human actions” (Ajzen & Fishbein, 1980, p. 13). According to Ajzen and 
Fishbein (1980), “people consider the implications of their actions prior to a decision to 
engage or not engage in each behavior” (p. 5). The goal of TPB is to describe the 
cognitive process of behaviors, focusing on a person’s choice or desire to engage in a 
specific behavior (Hale, Householder, & Greene, 2002). Intention has been identified as a 
significant predictor of behavior, leading to the belief that interventions must include 
models that promote intention-related strategies (Doswell, Braxter, Cha, & Kim, 2011). 
With consideration to external variables, which constitute the characteristics of a 
behavior, a person’s trust in the outcome of a behavior determines that person’s attitude 
towards that behavior (Montano & Kasprzyk, 2015).  
The TPB has been utilized in research which evaluated willingness to participate 
in clinical trials as the theoretical foundation. In a study conducted by Quinn et al. (2011) 
to explore the application of the theory of planned behavior to patients’ decisions about 
participating in a clinic trial, the results highlighted potential of the TPB as a useful tool 
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for investigating psychosocial needs as they relate to behavioral intention of clinical trial 
participation. This theory lends a benefit to my research because provides a perspective 
that allows the researcher to evaluate individual intentions and attitudes towards 
participation in clinical trials, as well as consider objective norms that influence this 
behavior, thus highlighting behavioral intent. My research considered that subjective 
norms are affected by an individual’s perceptions of his/her family’s and social beliefs, 
i.e. a consideration of whether these close social networks will approve or disapprove of 
the planned behavior (Ajzen & Fishbein, 1980). The constructs of social influence, which 
exerts its impact through different routes, was measured in the framework of attitudes and 
self-efficacy opportunities, intention, and past behavior (Vries et al., 1995). Social 
influence was defined as an individual’s conformity, compliance, and obedience to social 
factors within the community with which the individual identifies (Vries et al., 1995). 
Summary 
In this section, I discussed the issue of low participation in clinical trials among 
African Americans in the United States, using literature to show the significance of this 
issue. Though well documented in various reports, bridging this wide participation gap 
has been a daunting task for both researchers and pharmaceutical companies. Social 
factors which border around racism play a major role in promoting distrust of the 
healthcare community. Research has identified the existence of some level of willingness 
which may be diminished by the well-established beliefs developed through social 
influences, storytelling, and personal experiences. Conventional methods, which involve 
practices like the expansion of recruitment efforts, inclusion activities and information 
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sharing, have not been effective, thus highlighting the need for a creative approach to the 
identification of the antecedents to the distrust of this population for clinical trials. 
Interventions to improve participation must be culturally acceptable and consider all 
aspects of how distrust is learned through social interactions and storytelling. In the next 




Chapter 3: Research Method 
Introduction 
In Chapters 1 and 2, I discussed the historically low rate of participation of 
African Americans in clinical trials compared to other ethnicities despite multiple efforts 
made by researchers and federally funded agencies to offset these differences (see 
Hughes et al., 2015). Research has provided evidence that African Americans are less 
willing to participate in clinical trials due to a lack of trust of the research community as 
well as other socially modifiable factors (Boulware et al., 2016; Mokwunye & Nneka, 
2006). In this chapter, I will discuss the quantitative research method which was used to 
determine (a) the relationship between KAB towards clinical trials and African 
Americans’ willingness to participate in clinical trials and (b) whether social influence 
affects this group’s willingness to participate in clinical trials. The dependent variable 
was willingness to participate in clinical trials, and the independent variables were social 
influence and KAB towards research. 
Research Questions and Hypotheses 
The questions I developed for this study were primarily focused on the socio-
cultural factors that influence the willingness to participate in clinical trials among 
African Americans aged 18 and older. The following research questions and 
corresponding hypotheses guided this dissertation: 
Research Question 1: What is the relationship between knowledge of clinical 
trials and willingness to participate in clinical trials among African Americans? 
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H01: There is no statistically significant relationship between knowledge 
of clinical trials and willingness to participate in clinical trials among 
African Americans. 
HA1: There is a statistically significant relationship between knowledge of 
clinical trials and willingness to participate in clinical trials among African 
Americans. 
Research Question 2: What is the relationship between attitude and beliefs and 
willingness to participate in clinical trials among African Americans? 
H02: There is no statistically significant relationship between attitude and 
beliefs and willingness to participate in clinical trials among African 
Americans. 
HA2: There is a statistically significant relationship between attitude and 
beliefs and willingness to participate in clinical trials among African 
Americans. 
Research Question 3: Does social influence within the African American 
community affect the willingness of an African American to participate in clinical 
trials? 
H03: There is no statistically significant relationship between social 
influence within the African American community and the willingness of 
an African American to participate in clinical trials. 
34 
 
HA3: There is a statistically significant relationship between social 
influence within the African American community and willingness of an 
African American to participate in clinical trials. 
Study Design 
I conducted this study using a cross-sectional design to determine the prevalence 
of the lack of intended willingness to participate in clinical trials for this population as 
well as to collect data on individual characteristics, including exposure to social factors, 
alongside information about the outcome of interest. Quantitative data, in the form of a 
one-time questionnaire administered by paper instrument, were collected from research 
participants.  
Justification for Study Design 
This research design was acceptable for study because it is inexpensive and does 
not require a lot of time. The cross-sectional design also allows for multiple variables at 
the time data are collected as well as for outcomes and results to be analyzed to create 
new theories for future research (Frankfort-Nachmias & Nachmias, 2008). The 
quantitative research approach supports the research questions and allows for a higher 
level of objectivity and accuracy, aggregation, quantification of data, and a concise 
presentation of collective results (Lakshman et al., 2000). In addition, it is easy to design 
and implement surveys needed for a cross-sectional design, and the use of standardized 
surveys increases the reliability and comparability of research data (Lakshman et al., 
2000). Check and Schutt (2012) defined survey research as “the collection of information 
from a sample of individuals through their responses to questions” (p. 160). 
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Participants and Sampling Strategy 
The target population for this study was African Americans, aged 18 years and 
older, who resided in a greater metropolitan area of Ohio, and were able to sign an 
informed consent form. Only participants who met the study inclusion criteria were 
consented and allowed to participate in the study. I employed a sampling strategy in this 
study since it was not feasible to collect data from the entire African American 
population in the targeted greater metropolitan area of Ohio. Sampling strategies in 
survey research aim to attain an adequate sample that is representative of the population 
of interest (Ponto, 2015). To ensure a homogenous sample, the sampling frame included 
the members of up to 10 predominantly African American churches. I achieved access to 
this population through contact with the church leadership in person or via e-mail; they 
granted the necessary approval for me to approach their congregation for participation in 
this study. My initial assumption was that this approval would be granted if I provided 
proper information regarding the social implications of this research study to the church 
leaders. If necessary, I planned on expanding this sampling pool to include other 
predominantly African American organizations as needed to meet the statistical power 
requirements for the study. 
With approval from the church leadership, I approached the members of the 
congregation at specified times for informed consent and receipt of the surveys. To 
ensure only consenting participants completed the survey, the informed consent forms 
were attached to the surveys distributed to each participant. For the inclusion of the 
36 
 
members of the congregation who were not present at the specified times, I also sent the 
surveys via e-mail. 
Sample Size Calculation 
For the data analysis, I calculated a necessary sample size of 371 participants using the 
formula outlined in Figure 2. For this calculation, I used data from the U.S. Census Bureau 
(2016) report for the city and African American population estimate. Power analysis for a 
regression analysis with two predictors was conducted in G*Power using an alpha of 0.05, a 
power of 0.80, and a medium effect size (f2 = 0.15) to determine that out of the sample size of 
376, a minimum of 43 responses were required to achieve 80% power.  
        Z2 * (p) * (1-p) 
SS = ------------------- 
   c2 
Z = Z value (1.96 for 95% confidence level)  
p = African American population percentage > 18 years expressed as decimal (41% = .41) 
c = confidence interval, expressed as decimal (.05) 
Figure 2. Sample size calculation formula. p represents data from U.S. Census Bureau (2016). 
Data Collection 
I provided eligible participants with an informed consent form that highlighted the 
objectives of the study as well as the risks and benefits of participation. Participation was 
not mandated, and no names or other identifying information were collected from the 
participants. Data were collected using a self-administered questionnaire, which was 
distributed to members of 6 predominantly African American churches in a greater 
metropolitan area of Ohio. A self-administered survey is specifically designed for 
completion by participants in the research without the involvement of an interviewer 
(Lavrakas, 2008). The use of self-administered questionnaires has been demonstrated to 
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be inexpensive, while requiring less involvement on the part of the researcher; it creates a 
valuable and valid approach, providing clarity in the method used to explore and explain 
variables and theories of interest (Ponto, 2015). I disseminated paper surveys to the 
members of the church congregation who had consented to participate in this study. 
Participants were allowed privacy and adequate time to complete the survey within the 
church premises, and sealed submission boxes were provided to ensure the anonymity of 
all submissions. 
Instrumentation 
For this study, I developed a survey to include the factors identified in the 
literature review as having an impact on the willingness to participate in clinical trials. I 
developed the survey myself because there was no readily available survey that captured 
all the items needed to answer the research questions of this study. I identified four 
validated scales and used them in combination to develop different sections of the survey 
for this study, including: The Perceived Social Influence on Health Behavior Instrument 
(PSI-HBS; Holt et al., 2010), the Distrust of the Healthcare System Scale (DHS; 
Katapodi, Pierce, & Facione, 2010), the Group-Based Medical Mistrust Scale (GBMMS; 
Thompson et al., 2004), and the Attitudes and Factors Affecting Young Adults’ 
Willingness to Participate in Clinical Research Scale (Brandt, 2013). Adequate effort was 
made to ensure that proper permissions were obtained as needed for the use of these 
instruments. Following the development of the new survey, an expert review panel 




Description of Instruments and Validation Studies 
Perceived Social Influence on Health Behavior Scale (PSI-HBS) 
The PSI-HBS (Holt et al., 2010) is readily available in the public domain with no 
restrictions on utilization for research purposes. The scale was developed to evaluate the 
perceived part played by others in the health behavior choices and decisions of 
individuals and consists of 10 items assessed in 4-point, Likert-type format (strongly 
disagree, disagree, agree, and strongly agree). The researchers measured perceived 
social influence on health behavior based on utilitarian influence, value-expressive 
influence, and informational influence (Holt et al., 2010). The instrument has a possible 
range of 10–40, with higher scores indicative of higher levels of beliefs (Holt et al., 
2010). The PSI-HBS was validated through a series of six systematic steps: review of 
literature to locate existing scales, modification of existing instrument items, cultural 
appropriateness and face validity review of item, item revision, finalization of instrument, 
and psychometric testing of final instrument (Holt et al., 2010). Test-retest reliability was 
determined by administering the instrument via telephone to a national probability 
sample of 55 African Americans, and item-total correlations, internal consistency, 
discriminant validity, and factorial validity were determined administering the instrument 
by telephone to another national probability sample of African Americans (Holt et al., 
2010). African Americans, aged 21 years and older, living in a private residence with a 
telephone were recruited by professional interviewers with contact information randomly 
selected from a nationally representative pool developed based on census tract (Holt et 
al., 2010). The internal consistency of the overall instrument was α = .90 (with subscales 
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reported as α = .84 for utilitarian influence, α = .85 for value-expressive influence, and α 
= .81 for informational influence; Holt et al., 2010). 
Distrust of the Healthcare System Scale (DHS) 
The DHS (Katapodi et al., 2010) is readily available in the public domain with no 
restrictions on utilization for research purposes. This four-item scale addresses the 
negativity and confirmatory biases, targeting distrust as an influencer of health behavior 
and was developed within the framework of a study of if, and in what way, distrust of the 
health system and tendency to use healthcare services influence frequency of 
mammograms and clinical breast exams (Katapodi et al., 2010). The internal reliability 
and convergent validity of the DHS scale were supported when administered to a 
multicultural sample of 184 women (Cronbach alpha = 0.71; Katapodi et al., 2010). 
Responses are made on a 4-point, Likert-type scale (strongly agree to strongly disagree) 
where higher scores indicate greater distrust. 
Group-Based Medical Mistrust Scale (GBMMS) 
The GBMMS (Thompson et al., 2004) is readily available in the public domain 
with no restrictions on utilization for research purposes. It was developed to measure 
suspicion of health care systems and professionals using a 12-item Likert scale ranging 
from 1 (strongly disagree) to 5 (strongly agree) with a 12 to 60 score range. Validation 
was achieved in a study which investigated the psychometric properties of GBMMS and 
its association with cancer screening attitudes and breast cancer screening practices 
among African American and Latina women (Thompson et al., 2004). The results 
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supported the validity of the scale and suggested that the scale can be used to investigate 
medical mistrust (Thompson et al., 2004). 
Measures 
The new survey incorporated only components of existing validated instruments 
which address the research questions for this study. No modifications to the wordings 
were made in the new survey. The survey started with an introduction which covered the 
purpose of the study, definition of clinical trials, participants’ rights to their preference to 
answer or refuse to answer any of the questions, an acknowledgement of gratitude and 
instructions for submitting the survey. The survey was divided into multiple sections for 
ease of data collection. Appropriate Institutional Review Board approval was obtained for 
the final instrument. The following measures were captured in the survey: 
KAB: The survey included questions that were used to examine demographic and 
informational factors which are associated with knowledge attitudes and beliefs regarding 
clinical trials, as well as identified by previous research as potentially impacting 
willingness to participate in clinical trials. 
• Demographic Factors: Demographic questions consisted of five items 
including: age, gender, race, ethnicity, and level of education. For this study 
level of education was used as a proxy for socioeconomic status. Education is 
often considered a critical indicator of socioeconomic status because it 
conveys information regarding earning potential across the lifespan of an 
individual (Shavers, 2007; Winkleby et al., 1992). 
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• Informational Factors: According to the theory of planned behavior, 
informational factors are part of the background factors that may affect an 
individual’s beliefs and attitude towards clinical trials. These informational 
factors are made up of knowledge acquired through both formal and informal 
education. Thus, participants were asked questions to determine if they have 
knowledge regarding clinical trials as well as the source of their knowledge. 
Items from the survey Attitudes and Factors affecting Young Adults’ Willingness to 
Participate in Clinical Research (Brandt, 2013) were utilized to capture data for this 
measure. 
Willingness to participate: Using a closed-ended response of “yes”, “no”, or 
“don’t know” / “unsure” response, the second section of the survey examined three 
different situations related to willingness to participate. These include: 
• Willingness to participate in a clinical trial related to the health of the 
individual completing the survey, 
• Willingness to participate in a clinical trial related to the health of a close 
friend or family member, and 
• Willingness to participate in a clinical trials study that only contributed to 
scientific knowledge. 
Items from the survey Attitudes and Factors affecting Young Adults’ Willingness to 
Participate in Clinical Research (Brandt, 2013) were used to develop this section. 
Social influence: The survey was made up of questions that aim to examine the 
perceived role of others in the health behavior choices and decisions of individuals and 
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consists of 10 items assessed in four-point Likert-type format (strongly disagree, 
disagree, agree, strongly agree, neither disagree nor agree). Items from the PSI-HBS 
(Holt et al., 2010) were used to develop this section of the survey. 
Distrust: The survey included items from the GBMMS (Thompson et al., 2004) 
and the DHS (Katapodiet al., 2010) to assess individual and group levels of distrust 
among participants in this research study. 
Data Analysis Plan 
Descriptive statistics was used to characterize the study population. 
Frequency/percentage were reported for categorical variables (race, gender, 
socioeconomic status, education etc.) while mean and standard deviation were reported 
for continuous variables (age). Our outcome of interest is willingness to participate in 
clinical trials. Our predictors of interest include social influence, distrust of the health 
care system, demographic and informational factors. Regression and correlation analyses 
were utilized to assess if willingness is associated with any predictor of interest. A final 
regression model was performed to jointly test the associations between willingness and 
all the potential predictors. The regression model included the significant 
predictors/variables as covariates to account for potential confounding. The study 
population was characterized and the association between demographic variables and 
willingness to participate in clinical trial were described. Categorical variables were 
reported as percentages and for continuous variables, descriptive statistics were presented 
as means with standard deviations. 
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A p value adjustment can be used to control for family-wise error rate in a study 
with multiple hypotheses. However, given the exploratory nature of this study, a nominal 
p value threshold (p < 0.05) was applied for significance. All the analyses were 
performed in the Statistical Package for Social Sciences (SPSS). 
These analyses were guided by the following aims of the study and only the items 
which address these aims were utilized from the validated scales:  
• Aim 1: To describe the associations between KAB and willingness to 
participate in clinical trials among African Americans age 18 years and over. 
Correlation analyses were employed to test the association and to examine the 
direction of the association (positive or negative). 
• Aim 2: To describe the associations between social influence and willingness 
to participate in clinical trials among African Americans age 18 years and 
over. Correlation analyses were employed to test the association and to 
examine the direction of the association (positive or negative). 
Summary 
In this section, I discussed the research design, study population, sample size 
consideration, instrumentation, and data analysis plan. I provided a detailed review of the 
planned analysis for this study which ensured that the research questions were adequately 
answered.  I was aware of various opportunities for additional analyses with collected 
data but focused on the analyses that satisfied the current study, as well as set the stage 
for future studies. In the next chapter, the results of the analyses of the data collected for 
the study will be presented. 
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Chapter 4: Results 
Introduction 
The purpose of this quantitative study was to estimate the role of social influence 
in potentially diminishing the willingness of African Americans, 18 years old or older, to 
participate in clinical trials. In this study, I aimed to determine (a) the relationship 
between KAB towards clinical trials and African Americans’ willingness to participate in 
clinical trials and (b) whether social influence affects their willingness to participate in 
clinical trials. Quantitative data, in the form of a one-time questionnaire administered by 
paper instrument, were collected from research participants. I measured social influence 
and willingness to participate in clinical trials using items from the PSI-HBS (Holt et al., 
2010) and Attitudes and Factors Affecting Young Adults’ Willingness to Participate in 
Clinical trials survey (Brandt, 2013) respectively. All survey instruments were utilized 
with permissions from their respective authors.  
As discussed in the previous chapter, I used a cross-sectional design to estimate 
the prevalence of the outcome of interest for this population as well as to collect data on 
individual characteristics, including exposure to social factors, alongside information 
about the outcome of interest. This research design allowed for the inclusion of multiple 
variables at the time data were collected. Regression and correlation analyses were used 
to assess the relationship between willingness and any predictor of interest. 
In this chapter, I will present the research questions, specific aims of the study, 
data collection process, study results, and the summary of the study. Narratives will be 
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used to discuss study results and answer the following research questions with the aim of 
either failing to reject or rejecting the null hypothesis: 
Research Question 1: What is the relationship between knowledge of clinical 
trials and willingness to participate in clinical trials among African Americans? 
H01: There is no statistically significant relationship between knowledge 
of clinical trials and willingness to participate in clinical trials among 
African Americans. 
HA1: There is a statistically significant relationship between knowledge of 
clinical trials and willingness to participate in clinical trials among African 
Americans. 
Research Question 2: What is the relationship between attitude and beliefs and 
willingness to participate in clinical trials among African Americans? 
H02: There is no statistically significant relationship between attitude and 
beliefs and willingness to participate in clinical trials among African 
Americans. 
HA2: There is a statistically significant relationship between attitude and 
beliefs and willingness to participate in clinical trials among African 
Americans. 
Research Question 3: Does social influence within the African American 




H03: There is no statistically significant relationship between social 
influence within the African American community and the willingness of 
an African American to participate in clinical trials. 
HA3: There is a statistically significant relationship between social 
influence within the African American community and willingness of an 
African American to participate in clinical trials. 
Data Collection 
I collected data for this study using a self-administered questionnaire, which was 
distributed to members of 6 predominantly African American churches in a greater 
metropolitan area of Ohio. Following the receipt of approval from the Walden University 
Institutional Review Board (Approval Number 05-21-18-0572997), paper surveys were 
distributed to the members of each church congregation, 18 years and older, who 
consented to participate in this study. Out of the 10 African Methodist Episcopal 
Churches approached, six agreed to allow me access to their congregation for this study. 
Over a period of 12 weeks, 300 study surveys were distributed, and 119 surveys were 
completed and collected. I deemed four completed surveys unusable because the 
demographic and other pertinent data were missing, so these participants who did not 
indicate their race and/or age were not included in the analysis. The completed surveys 
were securely stored, and data from the surveys were double entered into a password-
protected computer file for analysis. No participant identifiable information was collected 
on the surveys, so no participant can be linked back to their completed survey. 
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Review of Survey Responses 
Demographic Factors 
All respondents were African American, and there were 48 males (42%) and 67 
females (58%). With an average age of 52 years, 35% (n = 40) of respondents were ages 
18 to 44 years, 37% (n = 42) were ages 45 to 64 years, 22% (n = 25) were ages 65 to 74 
years, and 7% (n = 8) were ages 75 years and above. Most of the respondents had 
received formal education with only 14 (12.2%) reporting not having a high school 
diploma or general education development (GED). Table 1 provides a detailed summary 
of the demographic characteristics of the survey respondents. 
Table 1  
 
Descriptive Statistics for Demographic Variables  
 % n M 
Gender    
  Male 41.7 48  
  Female 58.3 67  
Age (in years)   52 
  18–44 34.8 40  
  45–64 36.5 42  
  65–74 21.7 25  
  75 and above 7.0 8  
Education    
   No high school diploma  12.2 14  
   Undergraduate degree 33.9 39  
   Graduate degree 15.7 18  
   Postgraduate degree 6.1 7  
Note. N = 115. 
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When asked about their health status, respondents answered that they are 
generally healthy, reporting their health to be excellent (3.5%), very good (40%), good 
(47.8%), and fair (8.7%). A majority of respondents reported not having an illness that 
lasted more than 3 months (65.2%) and not being hospitalized in the past year (76.5%). 
When asked if a family member or friend had been ill or had an illness that lasted more 
than 3 months, approximately half of the respondents (52.2%) gave a positive response. 
Table 2 provides details of reported health status. 
Table 2 
 
Reported Health Status  
 % n 
Excellent 3.5 4 
Very good 40.0 46 
Good 47.8 55 
Fair 8.7 10 
Note. N = 115.  
Informational Factors 
Formal education. To assess the impact of formal education in their knowledge 
of clinical trials, I asked respondents about “the education I received during school 
included learning about clinical trials.” Respondents (see Table 3) did not believe that the 
education they received during school improved their knowledge about clinical trials with 
a majority answering that they disagreed (63.5%) or strongly disagreed (13%). A smaller 
number of respondents reported that they agreed (8.7%) or strongly agreed (2.6%) that 
the education they received through formal schooling improved their knowledge about 






 % n 
The education I received during school included learning about clinical trials… 
Strongly agree 2.6 3 
Agree 8.7 10 
Not sure 8.7 10 
Disagree 63.5 73 
Strongly disagree 13.0 15 
Prefer not to answer 3.5 4 
Note. N = 115.  
To assess respondents’ knowledge of clinical trials, I presented seven questions 
(i.e., three questions related to process/procedures of clinical trials and four questions 
related to the informed consent process) in the survey. A review of responses to the three 
questions that assessed knowledge associated with the procedures of clinical trials 
revealed that a high number of the respondents were not familiar with the clinical trials 
process. Twenty-one percent (n = 25) of respondents agreed that the statement “clinical 
trials studies determine how well treatment works” was sometimes true, and only one 
respondent (0.9%) agreed that this is always true. Similar responses were provided to the 
other two questions: (a) “Clinical researchers start with a set of research questions they 
want to answer before starting clinical trials studies,” with 22.6% responding sometimes 
true, and only one (0.9%) responding agreed to this being always true; and (b) “In a 
randomized clinical trials study, you get to choose the treatment you want,” with 16.5% 
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responding sometimes true, and only one (0.9%) respondent agreed to this being always 
true.  
The responses to questions used to assess respondents’ knowledge of the 
existence of a regulated informed consent process aimed at protecting the safety of 
participants in clinical trials showed that most of the participants did not understand the 
process of informed consent. Regarding awareness of participants, 19 respondents 
(16.5%) agreed this is sometimes true, and one respondent (0.9%) agreed that this is 
always true. Regarding awareness of potential participation risk, 13 respondents (11.3%) 
agreed this is sometimes true, and no respondent agreed that this is always true. 
Regarding awareness of potential benefits to participants, 20 respondents (17.4%) agreed 
this is sometimes true, and no respondent agreed that this is always true. Finally, 
regarding possible coercion to participate in clinical trials, 23 respondents (20%) agreed 
this is sometimes true, and four respondents (3.5%) agreed that this is always true. 
Overall, a high percentage of participants stated that they were unsure in all categories, 
which shows a high level of misinterpretation of the regulated process of clinical trials. 
Table 4 provides a complete report of respondents’ knowledge scores. 
Table 4 
 
Knowledge about Clinical Trials 
 n % 
Clinical trials studies determine how well treatment works 
Prefer not to answer 23 20.0 
Don’t know/unsure 63 54.8 
Never 1 .9 
Rarely 2 1.7 
                                                                                                                   (table continues) 
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Clinical trials studies determine how well treatment works 
Sometimes 25 21.7 
Always 1 .9 
Clinical researchers start with a set of research questions they want to answer 
before starting clinical trials studies 
Prefer not to answer 22 19.1 
Don’t know/unsure 63 54.8 
Rarely 3 2.6 
Sometimes 26 22.6 
Always 1 .9 
In a randomized clinical trials study, you get to choose the treatment you want 
Prefer not to answer 21 18.3 
Don’t know/unsure 71 61.7 
Never 1 .9 
Rarely 2 1.7 
Sometimes 19 16.5 
Always 1 .9 
Told that they are participating in a research project 
Prefer not to answer 10 8.7 
Don’t know/unsure 73 63.5 
Rarely 12 10.4 
Sometimes 19 16.5 
Always 1 .9 
Told about the possible risks of the clinical trials study 
Prefer not to answer 17 14.8 
Don’t know/unsure 83 72.2 
Never true 1 .9 
Rarely true 1 .9 
Sometimes true 13 11.3 
Told how they might benefit from the clinical trials study 
Prefer not to answer 26 22.6 
Don’t know/unsure 65 56.5 
Never true 2 1.7 
Rarely true 2 1.7 
Sometimes true 20 17.4 
                                                                                                                     (table continues) 
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Told they must participate in order to receive medical care 
Prefer not to answer 7 6.1 
Don’t know/unsure 52 45.2 
Never true 22 19.1 
Rarely true 7 6.1 
Sometimes true 23 20.0 
Always true 4 3.5 
Note. N = 115.  
Informal education. Using the following questions, I asked respondents if they 
had participated or ever been asked to participate in a clinical trial to assess their 
knowledge of clinical trials:  
• Prior to today, have you ever been asked to participate in a clinical trials 
project?  
• Prior to today, have you ever participated in a clinical trials project? 
• To the best of your knowledge, has someone close to you, such as a family 
member or friend, ever participated in a clinical trials project? 
Less than a fourth of the respondents (n = 23) reported that they had been asked to 
participate in a previous clinical trial (20%), and 19 respondents (16.5%) reported that 
they had participated in a previous clinical trial. A small group of respondents (13.9%) 
reported knowing someone close (family member or friend) who had participated in a 
clinical trial. The rest of the responses included respondents who did not know or chose 






Prior participation in Clinical Trials 
 n % 




































Note. N = 115.  
Beliefs and Attitudes About Clinical Trials 
To assess behavioral beliefs and attitudes about clinical trials, respondents were 
asked a series of questions aimed at measuring attitudes, beliefs, and stance on clinical 
trials, as well as trust in researchers. The five-item statement scale below was used to 
assess attitudes and beliefs about clinical trials: 
• Clinical trials will result in cures for many diseases. 
• Research on humans goes against my religious beliefs. 
• If I donate blood, for example to the Red Cross, it would be OK with me to 
use a small part of it (1 tablespoon) for research. 
• If I had surgery, I would be willing to allow the use of some of my surgical 
tissue for clinical trials. 
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• I would allow my name to be put on a registry or list to be contacted for future 
research. 
Individual item scores were added to produce a raw score, which was used to 
calculate the percent score. According to the scoring system specified by the developer 
Al-Jumah et al. (2011), positive attitude statements were scored from 5 (strongly agree) 
to 1 (strongly disagree). Percent score greater than 60% were considered positive attitude 
while a score less than 60% score was considered negative. The sample mean was 53.4% 
(median = 52%, SD = 12.31), thus indicating that most respondents had a negative 
attitude towards clinical trials (72%). Based of review of individual scores, most of the 
respondents agreed that clinical trials will result in cures for many diseases (52.2%) and 
reported that clinical trials do not go against their religious beliefs (49.6%). Most 
respondents would allow use of some of their blood in research (60%), as well as tissue 
(52.2%). Most respondents reported that they would allow their names to be added to a 
registry for future research contact (31.3%). Table 6 below shows the individual scores. 
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Table 6  
Beliefs and Attitudes About Clinical Trials 
 n % 
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Note. N = 115.    
56 
 
In addition to measuring attitudes and beliefs, respondents were also asked if they 
favor or oppose the use of human beings for clinical trials. Responses were based on a 5-
point Likert scale (5 = strongly favor, 4 = favor, 3 = neutral, 2 = oppose, 1 = strongly 
oppose). Most of the respondents reported that they were neutral to this question (40.9%) 
and a handful (11.3%) were not sure. To review the positive responses, a combination of 
“strongly favor” and “favor” responses indicated that about half of the respondents 
(40.9%), favored the use of humans in clinical trials. Table 7 provides the details of 
responses. 
Table 7  
Favoring Human Score 
 n % 
In general, would you say that you favor or oppose the use of 























 Note. N = 115.  
Social Influence on Health Behavior  
 Respondents were asked a series of questions to assess to evaluate the perceived 
part played by others in the health behavior choices and decisions. These 10 items were 
assessed in 4-point Likert-type format (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = 
strongly agree). Perceived social influence on health behavior was measured based on 
utilitarian influence, value-expressive influence, and informational influence. The 
instrument has a possible range of 10–40, with higher scores indicative of higher levels of 
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beliefs (Holt et al., 2010). The responses to the 10 survey questions were totaled to 
produce raw scores. Respondents social influence on behavior scores ranged from 10 to 
30 (mean = 20.77; SD± = 4.11). These scores indicate that, in general, respondents’ 
health behaviors are impacted by social influence. A review of the individual responses 
showed that majority of respondents (55%) will seek advice from friends regarding health 
behaviors for which they have limited knowledge. Table 8 below provides details on 




Table 8  
 
Social influence on health behavior 
 n % 
I rarely engage in health behaviors until I am sure my friends approve of them 
 Strongly disagree 28 24.3 
Disagree 69 60.0 
Agree 15 13.0 
Strongly agree 3 2.6 
It’s important that others agree with my health lifestyle (before I act) 
 Strongly Disagree 23 20.0 
Disagree 68 59.1 
Agree 17 14.8 
Strongly agree 2 1.7 
 Missing 5 4.3 
 
When engaging in health behaviors, I generally do things that I think others will 
approve of. 
 Strongly disagree 31 27.0 
Disagree 75 65.2 
Agree 9 7.8 
Strongly agree 0 0 
I like to know what health behaviors make good impressions on others 
 Strongly disagree 18 15.7 







I achieve a sense of belonging by making the same healthy choices that others do 
 Strongly Disagree 27 23.5 
Disagree 67 58.3 
Agree 16 13.9 
Strongly agree 4 3.5 
 Missing 1 .9 
If I want to be like someone, I often try to make the same healthy choices that they 
do 
 Strongly disagree 26 22.6 
Disagree 62 53.9 
                                                                                                                     (table continues) 
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If I want to be like someone, I often try to make the same healthy choices that they 
do 
 
 Agree 23 20.0 
Strongly agree 3 2.6 
 Missing 1 .9 
I often identify with other people by making the same healthy choices that they do 
 Strongly disagree 26 22.6 
Disagree 72 62.6 
Agree 15 13.0 
Strongly agree 2 1.7 
If I have little experience with a health behavior, I often ask my friends about it 
 Strongly disagree 17 14.8 
Disagree 40 34.8 
Agree 55 47.8 
Strongly agree 3 2.6 
I often consult other people to help choose the best alternative available for a health 
behavior 
 Strongly disagree 18 15.7 
Disagree 45 39.1 
Agree 49 42.6 
Strongly agree 3 2.6 
I frequently gather information from friends and family before I engage in a health 
behavior 
 Strongly disagree 7 6.1 
Disagree 55 47.8 
Agree 48 41.7 





Measuring Distrust of Healthcare System 
 The level of distrust of the healthcare system was evaluated using a four-item 
DHS, developed by Katapodi et al., 2010) and a 12-item GBMMS developed by 
Thompson et al. (2004). For the DHS, responses are made on a 4-point Likert-type 
scale (strongly agree to strongly disagree) with a 4 to 16 score range, where higher 
scores indicate greater distrust. For the GBMMS, possible responses were scored from 5 
(strongly agree) to 1 (strongly disagree) with a 12 to 60 score range (higher scores 
indicating higher level of distrust). The responses to the questions in each scale were 
totaled to produce raw scores. A review of the DHS responses showed that respondents’ 
distrust for health care providers scores ranged from 5 to 13 (mean = 8.53; SD± = 1.546). 
These scores indicate that, in general, respondents’ do not have high level of trust for 
their health care providers. The GBMMS results review showed scores ranging from 18 
to 46 (mean = 32.59; SD± = 3.651), indicating, like the DHS, that respondents have a low 
level of trust for health care providers. A review of the individual responses from the 
DHS showed that 70% of respondents disagree, and 15.7% strongly disagree with the 
statement “I trust my health care providers.” In the GBMMS, 39% of the respondents did 
not believe that African Americans received the same care from doctors and health care 
workers as people from other ethnic groups. Table 9 provides details on individual 






Measuring Distrust in Health Care Providers  
 n % 
I trust my healthcare providers 
Strongly disagree 18 15.7 
Disagree 81 70.4 
Agree 5 4.3 
Strongly agree 11 9.6 
I always believe someone when they say that their healthcare provider 
hasn’t been nice to them 
Strongly disagree 6 5.2 
Disagree 64 55.7 
Agree 40 34.8 
Strongly agree 5 4.3 
In general, the healthcare system is not sensitive to the patients’ needs. 
Strongly disagree 12 10.4 
Disagree 65 56.5 
Agree 33 28.7 
Strongly agree 4 3.5 
I’ve been treated poorly by healthcare providers often more than I’ve 
been treated with respect 
Strongly disagree 25 21.7 
Disagree 85 73.9 
Agree 4 3.5 
Strongly agree 1 .9 
People from my ethnic group cannot trust doctors and health care 
workers 
Strongly disagree 15 13.0 
Disagree 34 29.6 
Neither 48 41.7 
Agree 10 8.7 
Strongly agree 8 7.0 
People from my ethnic group should be suspicious of information from 
doctors and health care workers 
Strongly disagree 8 7.0 
Disagree 54 47.0 
Neither 41 35.7 
Agree 8 7.0 
Strongly agree 4 3.5 




People from my ethnic group should not confide in doctors and health 
care workers because it will be used against them 
Strongly disagree 22 19.1 
Disagree 66 57.4 
Neither 20 17.4 
Agree 5 4.3 
Strongly agree 2 1.7 
People from my ethnic group should be suspicious of modern medicine 
Strongly disagree 20 17.4 
Disagree 61 53.0 
Neither 23 20.0 
Agree 10 8.7 
Strongly agree 1 .9 
Doctors and health care workers treat people of my ethnic group like 
“guinea pigs 
Strongly disagree 16 13.9 
Disagree 50 43.5 
Neither 29 25.2 
Agree 15 13.0 
Strongly agree 5 4.3 
Doctors and health care workers do not take the medical complaints of 
people of my ethnic group seriously 
Strongly disagree 7 6.1 
Disagree 59 51.3 
Neither 32 27.8 
Agree 15 13.0 
People of my ethnic group are treated the same as people of other 
groups by doctors and health care workers 
Strongly disagree 3 2.6 
Disagree 36 31.3 
Neither 23 20.0 
Agree 43 37.4 
Strongly agree 8 7.0 
People of my ethnic group receive the same care from doctors and 
health care workers as people from other groups 
Strongly Disagree 4 3.5 
Disagree 35 30.4 
Neither 31 27.0 
Agree 35 30.4 
Strongly Agree 10 8.7 
                                                                                              (table continues) 
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In most hospitals, people of different ethnic groups receive the same 
kind of care 
Strongly disagree 5 4.3 
Disagree 25 21.7 
Neither 31 27.0 
Agree 36 31.3 
Strongly agree 18 15.7 
Doctors have the best interests of people of my ethnic group in mind 
Strongly disagree 6 5.2 
Disagree 17 14.8 
Neither 43 37.4 
Agree 36 31.3 
Strongly agree 13 11.3 
Doctors and health care workers sometimes hid information from 
patients who belong to my ethnic group 
Strongly disagree 8 7.0 
Disagree 36 31.3 
Neither 32 27.8 
Agree 35 30.4 
Strongly agree 4 3.5 
I have personally been treated poorly or unfairly by doctors or health 
care workers because of my ethnicity 
Strongly disagree 16 13.9 
Disagree 63 54.8 
Neither 17 14.8 
Agree 16 13.9 
Strongly agree 3 2.6 
Note. N = 115. 
The Stated Intention of Willingness to Participate 
 For this study, three scenarios which have varying levels of risks were used to 
measure individual’s willingness to participate in clinical trials. For each scenario, 
respondents’ perception of the physical risk associated with clinical trials was measured 
using the following responses on a Likert scale: “very safe”, “safe”, “neutral”, “risky”, or 
“very risky”. These were followed by questions regarding willingness to participate based 
on personal health benefit, adding to scientific knowledge, and benefit to someone close. 
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• Scenario 1 – You are asked to participate in a clinical trials study that 
consisted of taking a small amount of blood out of my arm 
• Scenario 2 – You are asked to participate in a clinical trials study that 
consisted of cutting off a small amount of skin (about the size of a pencil 
eraser), called a biopsy. This would require an injection (shot) of numbing 
medicine so that you did not have any pain and two to three sutures (stitches). 
The biopsy would be on a place where the scar would not be seen, such as 
you’re the top of your hip. There may be mild discomfort or pain for one to 
two days. 
• Scenario 3 – You are asked to participate in a clinical trials study that 
consisted of taking a medication (drug) that will have some side effects from 
the medicine, such as feeling sick to your stomach (nausea) or throwing up 
(vomiting). 
For Scenario 1 (blood draw), most respondents thought that it was safe (48.7%). 
Majority of the respondents asserted that they would be willing to take part in such 
research to benefit their own health (64.3%) and benefit the health of someone close to 
them (70.4%). However, willingness among respondents was decreased if the study only 
contributed to scientific knowledge (41.7%). Majority of the respondents (30%) thought 
that $50 was fair compensation for the stated scenario and assumed risk. 
For Scenario 2 (skin biopsy), respondents were evenly split on their assessment of 
the risk; safe (27.8%) vs. risky (28.7%). With regards to a benefit to their health, 
approximately half of the respondents (51%) expressed willingness to participate, one 
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third (33%) expressed willingness to participate to contribute to scientific knowledge, and 
over half (53.9%) expressed willingness to participate if it benefited someone close. The 
response to a “fair” compensation was almost evenly split between the choice of $100 
and $500 among respondents ($100 = 33% and $500 = 26.1%). 
For Scenario 3 (drug trial), majority of the respondents did not believe this was 
safe (risky = 38.3%; very risky = 25.2%). Only less than a fourth of the respondents 
(15.7%) thought it was either safe or very safe to take a drug with some side effects. 
About one third expressed willingness to participate to benefit their own health (31%), 
over half of respondents would not be willing to participate to add to scientific 
knowledge (54%), and about half of the respondents would be willing to participate to 
benefit someone close (43%). Majority of the respondents (40%) thought that the highest 
compensation ($500) was fair and commensurate with the risk. This was followed by a 
third of the respondents (26.1%) who thought $100 compensation was fair. 
Table 10  
Measuring Willingness to Participate and Compensation 
 n % 
Do you think the physical risk (the chance of being hurt or injured in this study) of 
this study is 
Very risky 1 .9 
Risky 11 9.6 
Neutral 31 27.0 
                                                                                                                     (table continues) 
   
Do you think the physical risk (the chance of being hurt or injured in this study) of 
this study is 
Safe 56 48.7 
Very safe 13 11.3 
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Prefer not to answer 3 2.6 
If you were asked today, would you be willing to take part in this clinical trial 
project if you felt it WOULD benefit your health now or in the future? 
Yes 74 64.3 
No 23 20.0 
Don’t know/unsure 14 12.2 
Prefer not to answer 4 3.5 
If you were asked today, would you be willing to take part in this clinical trial 
project if it would NOT benefit your health now or in the future but will add to 
scientific knowledge?   
Yes 48 41.7 
No 33 28.7 
Don’t know/unsure 29 25.2 
Prefer not to answer 5 4.3 
If you were asked today, would you be willing to take part in a study that you felt 
would NOT benefit YOUR health but would benefit the health of SOMEONE 
CLOSE TO YOU? 
Yes 81 70.4 
No 14 12.2 
Don’t know/unsure 19 16.5 
Prefer not to answer 1 .9 
If a person was willing to participate in Scenario 3, what do you think would be 
FAIR compensation? 
No compensation 9 7.8 
$5 8 7.0 
$10 10 8.7 
$50 38 33.0 
$100 26 22.6 
                                                                                                                     (table continues) 
If a person was willing to participate in Scenario 3, what do you think would be 
FAIR compensation? 
Prefer not to answer 24 20.9 
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Do you think the physical risk (the chance of being hurt or injured in this study) of 
this study is 
Very risky 12 10.4 
Risky 33 28.7 
Neutral 27 23.5 
Safe 32 27.8 
Very safe 5 4.3 
Prefer not to answer 6 5.2 
If you were asked today, would you be willing to take part in this clinical trial 
project if you felt it WOULD BENEFIT YOUR health now or in the future? 
Yes 59 51.3 
No 25 21.7 
Don’t know/unsure 26 22.6 
Prefer not to answer 5 4.3 
If you were asked today, would you be willing to take part in this clinical trial 
project if it would NOT benefit your health now or in the future but will add to 
scientific knowledge? 
Yes 38 33.0 
No 48 41.7 
Don’t know/unsure 28 24.3 
Prefer not to answer 1 .9 
If you were asked today, would you be willing to take part in a study that you felt 
would NOT benefit YOUR health but would benefit the health of SOMEONE 
CLOSE TO YOU? 
Yes 62 53.9 
No 25 21.7 
Don’t know/unsure 28 24.3 




If a person was willing to participate in Scenario 2, what do you think would be 
FAIR compensation? 
No compensation 1 .9 
$5 9 7.8 
$25 13 11.3 
$100 38 33.0 
$500 30 26.1 
Prefer not to answer 24 20.9 
Do you think the physical risk (the chance of being hurt or injured in this study) of 
this study is…? 
Very risky 29 25.2 
Risky 44 38.3 
Neutral 17 14.8 
Safe 17 14.8 
Very safe 1 .9 
Prefer not to answer 7 6.1 
If you were asked today, would you be willing to take part in this clinical trial 
project if you felt it WOULD benefit your health now or in the future? 
Yes 31 27.0 
No 36 31.3 
Don’t know/unsure 45 39.1 




If you were asked today, would you be willing to take part in this clinical trial 
project if it would NOT benefit your health now or in the future but will add to 
scientific knowledge? 
Yes 19 16.5 
No 54 47.0 
Don’t know/unsure 39 33.9 
Prefer not to answer 3 2.6 
                                                                                                                     (table continues) 
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If you were asked today, would you be willing to take part in a study that you felt 
would NOT benefit YOUR health but would benefit the health of SOMEONE 
CLOSE TO YOU? 
Yes 43 37.4 
No 25 21.7 
Don’t know/unsure 44 38.3 
Prefer not to answer 3 2.6 
If a person was willing to participate in Scenario 3, what do you think would be 
FAIR compensation? 
No Compensation 3 2.6 
$5 6 5.2 
$25 5 4.3 
$100 30 26.1 
$500 46 40.0 
Prefer not to answer 25 21.7 
Research Questions 
The theory of planned behavior, which serves as the conceptual framework for 
this study, highlights the existence of a linear path from KAB, to the intention of 
willingness to participate, to participation. Associations between knowledge, social 
beliefs and attitudes and willingness to participate in clinical trials were tested.  
RQ 1: What is the relationship between knowledge of clinical trials and willingness to 
participate in clinical trials among African Americans? 
H01: There is no statistically significant relationship between knowledge of 
clinical trials and willingness to participate in clinical trials among African 
Americans. 
HA1: There is a statistically significant relationship between knowledge of clinical 
trials and willingness to participate in clinical trials among African Americans. 
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As described earlier, three scenarios, with perceived physical risk increasing from 
the first to the third, were presented to the participants (Scenario 1: a blood draw; 
Scenario 2: a biopsy, an injection and sutures; and Scenario 3: anticipated side effects). 
Using response choices of “yes”, “no”, and “don’t know/unsure”, the following questions 
assessed the willingness to participate in three situations within each scenario: a) if the 
research would benefit that individual’s health, b) if the research would benefit the health 
of someone close to them, and c) if the research add to scientific knowledge. Total scores 
were computed for responses to the survey questions used to assess willingness as well as 
the survey questions used to assess knowledge of clinical trials. Higher scores in each 
case indicated a higher level of willingness and greater knowledge of clinical trials 
respectively. Regression and correlation analyses were utilized to test the association 
between knowledge of clinical trials and willingness to participate in trial. 
A Pearson Correlation (see Table 11) was used to test the relationship between 
Knowledge score 1 (three questions which assessed knowledge associated with the 
procedures of clinical trials) and Knowledge score 2 (four questions related to the 
informed consent process), and the overall willingness to participate score. The result 
showed a negative correlation between Knowledge 1 (-0.063) and Knowledge 2 (-0.045) 
and willingness to participate. Based on these results, we can accept the null hypothesis 
that there is no statistically significant relationship between knowledge of clinical trials 
and willingness to participate in clinical trials among African Americans. Knowledge of 
the procedures of clinical trials (p = 0.501) and the informed consent process (p = 0.635) 





Correlation Analysis of Knowledge of Clinical Trials and Willingness to Participate 
 Knowledge Score 1 Willingness Score 
Knowledge 
Score 1 
Pearson Correlation 1 -.063 
Sig. (2-tailed)  .501 
N 115 115 
Willingness 
Score 
Pearson Correlation -.063 1 
Sig. (2-tailed) .501  
N 115 115 
 Knowledge Score 2 Willingness Score 
Knowledge 
Score 2 
Pearson Correlation 1 -.045 
Sig. (2-tailed)  .635 
N 115 115 
Willingness 
Score 
Pearson Correlation -.045 1 
Sig. (2-tailed) .635  
N 115 115 
 
A linear regression analysis (see Table 12) was also conducted using 
“willingness” as the dependent variable, and the results showed that the R in the Model 
Summary equals Pearson Correlation. R-squared, which examines the goodness of fit, 
was 0.4% and 0.2% respectively, indicating a very poor goodness of fit. The regression 
coefficient shows that for each increase in knowledge by 1, there will be a decrease in 
willingness by 0.086 and 0.099 respectively.  
Table 12 
 




Model R R Square Adjusted R Square Std. Error of the Estimate 
1 .063a .004 -.005 5.006 







t Sig. B Std. Error Beta 
1 (Constant) 19.791 1.108  17.862 .000 
Knowledge Score -.086 .128 -.063 -.675 .501 
a. Dependent Variable: Willingness 
Additional analyses were conducted to test the association between knowledge of 
the procedures of clinical trials and each individual research scenario described earlier, 
used to assess willingness (Table 13). The results showed a negative correlation between 
knowledge and willingness in Scenario 1 and 3, and a positive correlation in Scenario 2. 
The results were consistent with the conclusion that knowledge of the procedures of 
clinical trials is not a valuable predictor of willingness to participate in clinical trials for 
Scenarios 1 and 2 (p = 0.620; 0.227). However, for Scenario 3, the results showed that 
knowledge of the procedures of clinical trials is a good predictor of willingness to 
participate in clinical trials which involve a higher risk to the participant (p = 0.010). 
Table 13  
 
Correlation Analysis of Knowledge of Clinical Trials and Willingness to Participate (All 
Scenarios) 
 Knowledge Score 1 Willingness Scenario 1 
Knowledge 
Score 
Pearson Correlation 1 -.047 
Sig. (2-tailed)  .620 





Pearson Correlation -.047 1 
Sig. (2-tailed) .620  
N 115 115 
 Knowledge Score 1 Willingness Scenario 2 
Knowledge 
Score 
Pearson Correlation 1 .114 
Sig. (2-tailed)  .227 
N 115 115 
Willingness 
Scenario 2 
Pearson Correlation .114 1 
Sig. (2-tailed) .227  
N 115 115 
 Knowledge Score 1 Willingness Scenario 3 
Knowledge 
Score 
Pearson Correlation 1 -.238* 
Sig. (2-tailed)  .010 
N 115 115 
Willingness 
Scenario 3 
Pearson Correlation -.238* 1 
Sig. (2-tailed) .010  
N 115 115 
*Correlation is significant at the 0.05 level (2-tailed). 
Analysis of the association between knowledge of the informed consent process in 
clinical trials and each individual research scenario also supported the conclusion that 
knowledge is not a valuable predictor of willingness to participate in clinical trials. 
Details of the p values are presented in Table 14. 
Table 14  
 
Correlation Analysis of Knowledge of Clinical Trials and Willingness to Participate (All 
Scenarios) 
 Knowledge Score 2 Willingness Scenario 1 
Knowledge 
Score 
Pearson Correlation 1 -.022 
Sig. (2-tailed)  .814 
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N 115 115 
Willingness 
Scenario 1 
Pearson Correlation -.022 1 
Sig. (2-tailed) .814  
N 115 115 
 Knowledge Score 2 Willingness Scenario 2 
Knowledge 
Score 
Pearson Correlation 1 .048 
Sig. (2-tailed)  .610 
N 115 115 
Willingness 
Scenario 1 
Pearson Correlation .048 1 
Sig. (2-tailed) .610  
N 115 115 
 Knowledge Score 2 Willingness Scenario 3 
Knowledge 
Score 
Pearson Correlation 1 -.143 
Sig. (2-tailed)  .126 
N 115 115 
Willingness 
Scenario 1 
Pearson Correlation -.143 1 
Sig. (2-tailed) .126  
N 115 115 
RQ 2: What is the relationship between attitude and beliefs and willingness to participate 
in clinical trials among African Americans? 
H02: There is no statistically significant relationship between attitude and beliefs 
and willingness to participate in clinical trials among African Americans. 
HA2: There is a statistically significant relationship between attitude and beliefs 
and willingness to participate in clinical trials among African Americans 
The results of a Pearson Correlation (Table 15) analysis of attitude and beliefs 
score and overall willingness score showed a positive correlation (0.357) between attitude 
and beliefs and willingness to participate in clinical trial (p = 0.000). This was confirmed 
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by the regression analysis (p = 0.000), and a regression coefficient which shows that for 
each increase in attitude and beliefs by 1, will result in an increase in willingness by 
0.449. 
Table 15  
 
Pearson Correlation Analysis of Attitude and Beliefs Score and Overall Willingness 
Score  
 Attitude/Belief Score Willingness  
Attitude/Belief 
Score 
Pearson Correlation 1 .357** 
Sig. (2-tailed)  .000 
N 115 115 
Willingness Pearson Correlation .357** 1 
Sig. (2-tailed) .000  
N 115 115 
 **. Correlation is significant at the 0.01 level (2-tailed). 
Model Summary 
Model R R Square Adjusted R Square Std. Error of the Estimate 
1 .357a .127 .119 4.687 







t Sig. B Std. Error Beta 
1 (Constant) 8.925 2.549  3.501 .001 
Attitude/Belief Score .449 .111 .357 4.057 .000 
a. Dependent Variable: Willingness 
Based on these results we can reject the null hypothesis in lieu of the alternative 
hypothesis that there is a statistically significant relationship between attitude and beliefs 
and willingness to participate in clinical trials among African Americans. Attitude and 
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beliefs about clinical trials is a good predictor of willingness to participate in clinical 
trials (p = 0.000). 
RQ 3: Does social influence within the African American community affect the 
willingness of an African American to participate in clinical trials? 
H03: There is no statistically significant relationship between social influence 
within the African American community and the willingness of an African American to 
participate in clinical trials. 
HA3: There is a statistically significant relationship between social influence 
within the African American community and willingness of an African American to 
participate in clinical trials. 
Understanding the impact of social influence on the willingness of African 
Americans to participate in clinical trials was the focus of this research question. Survey 
question used to assess social influence were obtained from the perceived social 
Influence on health behavior instrument which has a possible range of 10–40, with higher 
scores indicative of higher levels of beliefs. Pearson Correlation was used to test the 
association between perceived social Influence on health behavior score and willingness 
to participate score. As shown in Table 16, there was a negative correlation (-0.141) 
between social influence and willingness to participate in clinical trial, but with no 
statistical significance (p = 0.132). This was confirmed by the regression analysis (p = 
0.132), and a regression coefficient which shows that for each increase in attitude and 
beliefs by 1, will result in a decrease in willingness by 0.172. Based on these results, we 
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can accept the null hypothesis that there is no statistically significant relationship between 
social influence and willingness to participate in clinical trials among African Americans. 
Table 16  
 
Correlation Analysis of Social Influence and Willingness to Participate in Clinical Trials 
 PSI_HB SCORE Willingness 
PSI_HB SCORE Pearson Correlation 1 -.141 
Sig. (2-tailed)  .132 
N 115 115 
Willingness Pearson Correlation -.141 1 
Sig. (2-tailed) .132  
N 115 115 
 
Model Summary 
Model R R Square Adjusted R Square Std. Error of the Estimate 
1 .357a .127 .119 4.687 








t Sig. B Std. Error Beta 
1 (Constant) 22.684 2.396  9.468 .000 
PSI_HB Score -.172 .113 -.141 -1.519 .132 
a. Dependent Variable: Willingness 
Additional analyses were conducted to test the association between social 
influence and each individual research scenario described earlier, used to assess 
willingness. The results for Scenarios 2 and 3 were consistent with the conclusion that 
social influence is not a valuable predictor of willingness to participate in clinical trials (p 
= 0.943; 0.085). However, for Scenario 1, which represents the least risk to a research 
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participant, the results showed that social influence is a good predictor of willingness to 
participate in clinical trials (p = 0.047). 
Table 17  
Correlation analysis of Social Influence and Willingness to Participate in Clinical Trials 
(All Scenarios) 
 PSI_HB SCORE Willingness Scenario 1 
PSI_HB SCORE Pearson Correlation 1 -.185* 
Sig. (2-tailed)  .047 
N 115 115 
Willingness 
scenario 1 
Pearson Correlation -.185* 1 
Sig. (2-tailed) .047  
N 115 115 
Summary 
In this chapter, I provided a detailed overview and interpretation of the study 
results. Three research questions were evaluated using statistical analysis. The first 
research question evaluated the relationship between knowledge of clinical trials and 
willingness to participate in clinical trials among African Americans. The results showed 
that knowledge is not a valuable predictor of willingness to participate in clinical trials. 
The second research question evaluated the relationship between attitude and beliefs and 
willingness to participate in clinical trials among African Americans. The results showed 
that attitudes and beliefs about clinical trials is a good predictor of willingness to 
participate in clinical trials. The third research question evaluated the impact of social 
influence within the African American community on the willingness of an African 
American to participate in clinical trials. The results showed that social influence is a 
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good predictor of willingness to participate in clinical trials in trials that pose minimal 
risks to participants. Discussion of the findings will be presented in chapter 5.  
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Chapter 5: Discussion, Conclusions, and Recommendation 
Introduction 
The purpose of this quantitative study was to form a discussion regarding social 
influence and its impact on the willingness of African Americans, 18 years or older, to 
participate in clinical trials. I collected quantitative data, in the form of a one-time 
questionnaire administered by paper instrument, from research participants over a period 
of 12 weeks from June to August 2018. Social influence and willingness to participate in 
clinical trials were measured using items from the PSI-HBS (Holt et al., 2010) and 
Attitudes and Factors affecting Young Adults’ Willingness to Participate in Clinical 
Research survey (Brandt, 2013), respectively. In this study, I collected and analyzed data 
to address three research questions and corresponding hypothesis. Data were analyzed 
using correlation and regression analysis in SPSS. My aim was to understand the 
relationship between African Americans’ KAB towards clinical trials and willingness to 
participate in clinical trials and whether social influence affects their willingness to 
participate in clinical trials. 
Interpretation of Findings 
 The conceptual framework that I used for this study was Fishbein and Ajzen’s 
TPB. The use of this well-established and recognized social cognitive theory was 
applicable to this study because the model is based on beliefs that assume that the 
intention of an individual to exhibit a behavior is an important determinant for exhibiting 
that behavior (see Ajzen & Madden, 1986). The TPB provided a perspective that allowed 
me to evaluate individual intentions and attitudes towards participation in clinical trials as 
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well as consider objective norms that influence this behavior. In this study, I considered 
that subjective norms are affected by an individual’s perceptions of their family and 
social beliefs (i.e., a consideration of whether these close social networks will approve or 
disapprove of the planned behavior; see Ajzen & Fishbein, 1980). The constructs of 
social influence were measured in the framework of attitudes and self-efficacy 
opportunities, intention, and past behavior (see Vries et al., 1995). Social influence was 
defined as an individual’s conformity, compliance, and obedience to social factors within 
the community with which the individual identifies (Vries et al., 1995). 
Knowledge of Clinical Trials and Willingness to Participate 
A majority of the survey respondents did not believe that the education they 
received during school improved their knowledge about clinical trials (76.3%), were not 
familiar with the clinical trial process, and did not understand the process of informed 
consent. Only a small percent of participants reported having prior knowledge of clinical 
trials through their own or a family member’s participation. Researchers that examined 
the relationship between knowledge of clinical trials and willingness to participate and 
reported a positive correlation (i.e., Advani et al., 2003; Boulware et al., 2016; DeFreitas, 
2010) concluded that individuals who are more knowledgeable about issues related to 
clinical trials have more favorable attitudes toward clinical trials and are more willing to 
contemplate participation in a clinical trial (Ojukwu et al, 2018). However, for the first 
research question, I concluded that there is no statistically significant relationship 
between knowledge of clinical trials and willingness to participate in clinical trials among 
the African Americans surveyed for this study. Knowledge of the procedures of clinical 
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trials (p = 0.501) and the informed consent process (p = 0.635) were not valuable 
predictors of willingness to participate in clinical trials.  
Attitude and Beliefs and Willingness to Participate 
 To assess behavioral beliefs and attitudes about clinical trials, I asked respondents 
a series of questions aimed at measuring their attitudes, beliefs, and stance on clinical 
trials as well as their trust in researchers. Previously, other investigators have concluded 
that African Americans have more negative attitudes about clinical trials and as a result 
are less willing to participate (Pariera, Murphy, Meng, & McLaughlin, 2017). These 
negative attitudes are mostly fueled by the lack of trust in health care providers and an 
increasing interest in complementary and alternative medicine (Pariera et al., 2017).  
The findings from this study suggest that the respondents’ attitudes and beliefs 
were associated with their willingness to participate in clinical trials. There was a positive 
correlation (0.357) between attitudes and beliefs and willingness to participate in clinical 
trial (p = 0.000). This was confirmed by the regression analysis (p = 0.000), and a 
regression coefficient that shows that for each increase in attitudes and beliefs by 1, an 
increase in willingness by 0.449 will result. There is a statistically significant relationship 
between attitudes and beliefs and willingness to participate in clinical trials among 
African Americans. Attitudes and beliefs about clinical trials are a good predictor of 
willingness to participate in clinical trials (p = 0.000). 
Social Influence and Willingness to Participate 
 Understanding the impact of social influence on the willingness of African 
Americans to participate in clinical trials was the focus of this study. I obtained the 
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survey questions used to assess social influence from the PSI-HBS, which has a possible 
range of 10–40, with higher scores indicative of higher levels of beliefs. A Pearson 
correlation was used to test the association between PSI-HBS score and willingness to 
participate score. For the analysis, which included perceived social influence and all 
scenarios of clinical trials, the result was a negative correlation (-0.141) between social 
influence and willingness to participate in clinical trial but with no statistical significance 
(p = 0.132). This was confirmed by the regression analysis (p = 0.132), and a regression 
coefficient that shows that for each increase in perceived social influence by 1, a decrease 
in willingness by 0.172 will result. However, analyses to test the association between 
perceived social influence and each individual research scenario revealed that for 
Scenario 1, which represents the least risk to a research participant, social influence is a 
good predictor of willingness to participate in clinical trials (p = 0.047). Based on this 
finding, I rejected the null hypothesis in lieu of the alternative hypothesis that there is a 
statistically significant relationship between social influence and willingness to 
participate in clinical trials with minimal risk among African Americans. 
Limitations 
 There were limitations to this research. The response rate limited access to the 
desired study population. Only 115 participants completed the survey, which created a 
limitation since the analysis required a larger sample size to accurately detect statistically 
significant relationships between variables. The participants in this study were not 
representative of the entire African American population in a greater metropolitan area of 
Ohio because only church attendees who agreed to the research were included. Although 
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a previous study reported that religiously based differences on social issues are less 
evident among African-Americans compared to the overall population, with 53% of 
African Americans polled reporting attending religious services at least once a week 
(Sahgal & Smith, 2016), the result of this study may not be generalizable to the entire 
African American population because of differences in opinions that may exist among 
church goers vs. non-church goers. Another limitation was that all indication of 
willingness to participate in clinical trial was based on hypothetical scenarios, which may 
lead to responses that may not accurately reflect the individuals’ intention or future action 
(see Schoenberg & Ravdal, 2000). In the conduct of this study, there were variables 
whose presence could affect the variables of focus. A final limitation was that the 
analyses used in this study did not effectively control for these variables which were 
potential confounders. 
Recommendations 
 The results from this study provide evidence of the existence of a relationship 
between social influence and willingness to participate in clinical trials involving 
minimal risk among African Americans. In this study, I only evaluated responses from a 
small non-representative sample of African Americans, but future research should utilize 
a broader inclusion of this population and other ethnicities to efficiently detect this 
relationship. Confounders should be clearly identified and controlled in future research 
using Multivariate methods because there is a high potential for confounding even after 
data adjustment, leading to unjustified results. Additional analyses should also be 
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conducted to understand the roles played by socioeconomic factors in the process of 
formulating and retaining social norms in this population. 
Implications for Social Change 
Failure to increase the participation rates of African Americans in clinical trial 
will inhibit the progress of clinical trial research into novel and effective methods in drug 
development (Frew et al., 2015). I designed this study to identify how social influence 
affects African Americans’ willingness to participate in clinical trials as a platform for 
the development and implementation of interventions to improve clinical trial 
participation among this population. Researchers involved in the development of novel 
therapies can use the information from this study to improve the clinical trial patient 
recruitment process. A clear understanding of these social factors and how they interact 
to impact the health behavior of African Americans will create a path to the development 
of viable and sustainable intervention. 
Conclusion 
The purpose of this quantitative study was to identify the interactions between 
social influence and the intended willingness of African Americans to participate in 
clinical trials. The findings may be used as a platform for the development and 
implementation of interventions aimed at improving clinical trials participation among 
this population. In this study, I examined and elucidated the potential association between 
social influence and willingness of African Americans to participate in clinical trials. The 
results were in line with findings from existing literature; however, more research is 
needed to gain a better understanding of how social influence is developed and fostered 
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in the African American community. African Americans deserve the chance to be 
represented in the process of developing therapies aimed at treating diseases that burden 
their community, and the results of this study create a starting point for more research to 
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